Xceleron provides bioanalytical Accelerator Mass Spectrometry (AMS) services to accelerate early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. Led by CEO Michael Butler and Vice President Analytical Operations Stuart Best, Xceleron supports accelerated early drug development through these analyses. Founded in 1997 in York, UK, the company opened its US facility in Maryland in 2008. It plans to use the new funding to consolidate operations in Germantown, MD, relocate senior analytical staff from York, and hire new staff in Maryland while retaining a study design and project management presence in the UK. Xceleron recently raised $2.4M with backing from existing investors Albion Ventures and Solon Ventures. Xceleron provides human data and insights to drug developers to support early and well‑informed portfolio decisions and preclinical evaluation of proteins and other high molecular weight drugs. The company supplies reliable information about drug candidates across multiple clinical settings. Xceleron realized significant revenue growth in 2009 and now partners with most of the top 20 pharmaceutical companies. It supports clients by delivering important data earlier in clinical studies than was previously possible. Xceleron is based in York, UK and Germantown, MD. The company plans to use new funding to accelerate future growth and expand capacity in line with customer demand.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2012